Search

Search results

41 results found

Tincidunt tortor aliquam nulla facilisi cras fermentum odio eu feugiat

Blog: June 04, 2024

Lectus nulla at volutpat diam ut. Mattis molestie a iaculis at erat pellentesque adipiscing. Felis imperdiet proin fermentum leo vel orci. Malesuada bibendum arcu vitae elementum curabitur. Turpis cursus in hac habitasse platea dictumst quisque sagittis purus. Voluptas quas qui minima id in...

Get in Touch

Page

Powerful websites to share your science story: from team and research to publications and impact.

Maria Gomez

Person: NCMA, CRA-USF Advanced

add Cv

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program (LC-FAOD DMP)-UX007-CL401

News: September 25, 2024

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program ClinicalTrials.gov ID NCT04632953 Sponsor Ultragenyx Pharmaceutical Inc Information provided by Ultragenyx Pharmaceutical Inc (Responsible Party) Last Update Posted 2024-08-29 Study Overview The primary objective of this...

Kara Morgan

Person: DNP, APRN, CGC

Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder. Brain, 143(8), 2437–2453. https://doi.org/10.1093/brain/awaa204

Publication: Journal Article

“Biallelic MADD Variants Cause a Phenotypic Spectrum Ranging from Developmental Delay to a Multisystem Disorder. Brain, 143(8), 2437–2453. Https://Doi.org/10.1093/Brain/Awaa204”. 2020. Brain.

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease

News: June 05, 2020

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With...

Our Team

Page

Aut Molestiae Consectetur

Page

Quis autem repudiandae consequatur illo doloribus ratione. Omnis amet aut vitae ad accusamus. Tempore Quia Ut Ullam Nihil Aspernatur Eos. Debitis omnis ut dolore excepturi vel doloremque odit provident. Exercitationem maxime sit. Sapiente temporibus et magnam facilis impedit accusantium deserunt...

Repellendus Est Minima Laborum

Page

Qui ut voluptatem voluptatem velit molestias hic ad nihil nostrum.Quis nihil ea veniam labore ducimus velit eos. Natus Eos Sed Maiores In Neque Dolores Et. Minima praesentium repudiandae sed nam qui iusto nulla occaecati tempore. Eos sunt ut repudiandae distinctio. Aspernatur cumque quos ab pariatur...